The effect of methylene blue treatment on aspiration pneumonia

• Published in: The Journal of surgical research 2015-02, Vol.193 (2), p.909-919
• Main Authors: Kanter, Mehmet, PhD, Sahin, Sevtap Hekimoglu, MD, Basaran, Umit Nusret, MD, Ayvaz, Suleyman, MD, Aksu, Burhan, MD, Erboga, Mustafa, PhD, Colak, Alkin, MD
• Format: Article
• Language: English
• Subjects: Acute Lung Injury - etiology; Acute Lung Injury - pathology; Acute Lung Injury - prevention & control; Animals; Drug Evaluation, Preclinical; Enzyme Inhibitors - therapeutic use; Immunohistochemistry; In Situ Nick-End Labeling; iNOS; Lung - pathology; Methylene blue; Methylene Blue - therapeutic use; Pneumonia, Aspiration - complications; Pneumonia, Aspiration - drug therapy; Pneumonia, Aspiration - pathology; Pulmonary aspiration; Random Allocation; Rats, Sprague-Dawley; Surfactant protein D; Surgery; TUNEL
• ISSN: 0022-4804; 1095-8673
• DOI: 10.1016/j.jss.2014.08.039

Abstract Background The study aimed to examine whether methylene blue (MB) prevents different pulmonary aspiration materials-induced lung injury in rats. Methods The experiments were designed in 60 Sprague–Dawley rats, ranging in weight from 250–300 g, randomly allotted into one of six groups ( n  = 10): saline control, Biosorb Energy Plus (BIO), hydrochloric acid (HCl), saline + MB treated, BIO + MB treated, and HCl + MB treated. Saline, BIO, and HCl were injected into the lungs in a volume of 2 mL/kg. After surgical procedure, MB was administered intraperitoneally for 7 days at a daily dose of 2 mg/kg per day. Seven days later, rats were killed, and both lungs in all groups were examined biochemically and histopathologically. Results Our findings show that MB inhibits the inflammatory response reducing significantly ( P